Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDE397 + IDE892 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDE397 | IDE-397|IDE 397 | MAT2A Inhibitor 5 | IDE397 inhibits MAT2A, which may reduce synthesis of S-adenosyl-L-methionine (SAM), potentially leading to anti-tumor activity in MTAP-deficient cancers (Cancer Res 2021;81(13_Suppl):Abstract nr 1278). | |
| IDE892 | IDE-892|IDE 892 | PRMT5 Inhibitor 22 | Limited information is currently available on IDE892, a putative PRMT5 inhibitor (Jan 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07277413 | Phase I | IDE892 IDE397 + IDE892 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Recruiting | USA | 0 |